Real life evaluation of safinamide effectiveness in Parkinson’s disease View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-04

AUTHORS

Francesca Mancini, Alessio Di Fonzo, Giulia Lazzeri, Linda Borellini, Vincenzo Silani, Marco Lacerenza, Cristoforo Comi

ABSTRACT

In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100 mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson's disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson's Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD). Eight patients withdrew safinamide within the first month for minor side effects. At the follow-up evaluation, after a mean time with safinamide of 7.5 months ± 3.4, all patients showed a significant improvement of all the scale scores, except for HY, and of the daily dosages of the drugs and the LEDD. The same results were shown by PD patients treated with safinamide 50 mg and patients who started safinamide without switching from a previous MAOBI. PD patients with safinamide 100 mg and patients who started safinamide switching from a previous MAOBI significantly improved in time spent in OFF and LEDD. In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy. More... »

PAGES

733-739

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10072-018-3272-y

DOI

http://dx.doi.org/10.1007/s10072-018-3272-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1100993577

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29441484


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alanine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiparkinson Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzylamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dopamine Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Levodopa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Monoamine Oxidase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Parkinson Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Istituto Auxologico Italiano", 
          "id": "https://www.grid.ac/institutes/grid.418224.9", 
          "name": [
            "Department of Neurology\u2013Stroke Unit and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mancini", 
        "givenName": "Francesca", 
        "id": "sg:person.0635556432.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635556432.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Milan", 
          "id": "https://www.grid.ac/institutes/grid.4708.b", 
          "name": [
            "Neurology Unit, IRCCS Fondazione Ca\u2019 Granda Ospedale Maggiore Policlinico, \u201cDino Ferrari\u201d Center, Neuroscience Section, Department of Pathophysiology and Transplantation, Universit\u00e0 Degli Studi di Milano, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Fonzo", 
        "givenName": "Alessio", 
        "id": "sg:person.01351444372.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351444372.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Milan", 
          "id": "https://www.grid.ac/institutes/grid.4708.b", 
          "name": [
            "Neurology Unit, IRCCS Fondazione Ca\u2019 Granda Ospedale Maggiore Policlinico, \u201cDino Ferrari\u201d Center, Neuroscience Section, Department of Pathophysiology and Transplantation, Universit\u00e0 Degli Studi di Milano, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lazzeri", 
        "givenName": "Giulia", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Milan", 
          "id": "https://www.grid.ac/institutes/grid.4708.b", 
          "name": [
            "Neuropathophysiology Unit, IRCCS Foundation Ca\u2019 Granda Ospedale Maggiore Policlinico, Universit\u00e0 degli Studi di Milano, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Borellini", 
        "givenName": "Linda", 
        "id": "sg:person.0707350751.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707350751.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Milan", 
          "id": "https://www.grid.ac/institutes/grid.4708.b", 
          "name": [
            "Department of Neurology\u2013Stroke Unit and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy", 
            "Department of Neurology-Stroke Unit and Laboratory of Neuroscience, \u201cDino Ferrari\u201d Centre - Centre for Neurotechnology and Brain Therapeutics, Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Silani", 
        "givenName": "Vincenzo", 
        "id": "sg:person.01075440114.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075440114.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Neurology Service, Casa di Cura Humanitas San Pio X, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lacerenza", 
        "givenName": "Marco", 
        "id": "sg:person.01117517756.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117517756.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Eastern Piedmont Amadeo Avogadro", 
          "id": "https://www.grid.ac/institutes/grid.16563.37", 
          "name": [
            "Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Comi", 
        "givenName": "Cristoforo", 
        "id": "sg:person.01165766340.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165766340.84"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/brain/awu195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007870128"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/13543784.17.7.1115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009120017"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.23429", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009574356"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1038/sj.bjp.0703826", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017457033"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-015-0389-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017926421", 
          "https://doi.org/10.1007/s40265-015-0389-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.22341", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021776403"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0960-894x(99)00271-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027208426"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaneurol.2016.4467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029873011"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/dddt.s77749", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030879020"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1353-8020(97)00029-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034520022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3233/jpd-150569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035973287"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/brain/123.11.2297", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036535879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00702-012-0930-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038806006", 
          "https://doi.org/10.1007/s00702-012-0930-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/jnnp.55.3.181", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038938753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.25751", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045433382"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.67.7_suppl_2.s18", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064382308"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.67.7_suppl_2.s18", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064382308"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.67.7_suppl_2.s18", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064382308"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/156802611798184355", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069194220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074253470", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074654105", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0018578717726046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092203082"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0018578717726046", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092203082"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-04", 
    "datePublishedReg": "2018-04-01", 
    "description": "In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100\u00a0mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson's disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson's Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1\u00a0week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD). Eight patients withdrew safinamide within the first month for minor side effects. At the follow-up evaluation, after a mean time with safinamide of 7.5\u00a0months\u2009\u00b1\u20093.4, all patients showed a significant improvement of all the scale scores, except for HY, and of the daily dosages of the drugs and the LEDD. The same results were shown by PD patients treated with safinamide 50\u00a0mg and patients who started safinamide without switching from a previous MAOBI. PD patients with safinamide 100\u00a0mg and patients who started safinamide switching from a previous MAOBI significantly improved in time spent in OFF and LEDD. In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10072-018-3272-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1294956", 
        "issn": [
          "1590-1874", 
          "1126-5442"
        ], 
        "name": "Neurological Sciences", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "name": "Real life evaluation of safinamide effectiveness in Parkinson\u2019s disease", 
    "pagination": "733-739", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "3db87e55d592dfddadb88300b9664d13c0db67bde3060e508c117851315ddc87"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29441484"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100959175"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10072-018-3272-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1100993577"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10072-018-3272-y", 
      "https://app.dimensions.ai/details/publication/pub.1100993577"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000603.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s10072-018-3272-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10072-018-3272-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10072-018-3272-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10072-018-3272-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10072-018-3272-y'


 

This table displays all metadata directly associated to this object as RDF triples.

253 TRIPLES      21 PREDICATES      67 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10072-018-3272-y schema:about N018ee4fce60742df89ae6b07893481ea
2 N11f0cdf73b7348c4b3dad79b1db8e7ed
3 N12ff6d87332c4b4dba3b83589c4fbb48
4 N1a20ae4fb51c4991b2c30e0757a23393
5 N1eb5e7e3f1eb449aa104b51e30986db3
6 N20d09d1eb24e4c429bdd218e7bedc9c7
7 N3f91a3b3aa754eaca4407475ad1e273c
8 N493ce16e0feb4e3ebfaa7eae45e70675
9 N4e6f0d879c014dda891000950b47311b
10 N866c958d2d614105b3d36b98554e9a04
11 N8fa1ebcf87914df1a25da5f9df66774e
12 N925401ab25534ef08c828289faa0b1a3
13 Na9339e73447841babf01dd19abdf77b8
14 Naf9c5ebee2b74fc486949024744dde7b
15 Nb937536ef10f4a87a9e19858925fc10d
16 Ncabec5b59f5a41b3b75a56fe1823e3cc
17 Nccf9bc08bdfa4159813332802158d303
18 Nde6c4d1d7b65434c9f1f976b347a4b26
19 anzsrc-for:11
20 anzsrc-for:1109
21 schema:author Nf7a12b4ceb8340fb902e2a6707c7acc4
22 schema:citation sg:pub.10.1007/s00702-012-0930-8
23 sg:pub.10.1007/s40265-015-0389-7
24 https://app.dimensions.ai/details/publication/pub.1074253470
25 https://app.dimensions.ai/details/publication/pub.1074654105
26 https://doi.org/10.1001/jamaneurol.2016.4467
27 https://doi.org/10.1002/mds.22341
28 https://doi.org/10.1002/mds.23429
29 https://doi.org/10.1002/mds.25751
30 https://doi.org/10.1016/s0960-894x(99)00271-1
31 https://doi.org/10.1016/s1353-8020(97)00029-1
32 https://doi.org/10.1038/sj.bjp.0703826
33 https://doi.org/10.1093/brain/123.11.2297
34 https://doi.org/10.1093/brain/awu195
35 https://doi.org/10.1136/jnnp.55.3.181
36 https://doi.org/10.1177/0018578717726046
37 https://doi.org/10.1212/wnl.67.7_suppl_2.s18
38 https://doi.org/10.1517/13543784.17.7.1115
39 https://doi.org/10.2147/dddt.s77749
40 https://doi.org/10.2174/156802611798184355
41 https://doi.org/10.3233/jpd-150569
42 schema:datePublished 2018-04
43 schema:datePublishedReg 2018-04-01
44 schema:description In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100 mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson's disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson's Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD). Eight patients withdrew safinamide within the first month for minor side effects. At the follow-up evaluation, after a mean time with safinamide of 7.5 months ± 3.4, all patients showed a significant improvement of all the scale scores, except for HY, and of the daily dosages of the drugs and the LEDD. The same results were shown by PD patients treated with safinamide 50 mg and patients who started safinamide without switching from a previous MAOBI. PD patients with safinamide 100 mg and patients who started safinamide switching from a previous MAOBI significantly improved in time spent in OFF and LEDD. In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy.
45 schema:genre research_article
46 schema:inLanguage en
47 schema:isAccessibleForFree false
48 schema:isPartOf N956bc431d5bc4142aedc93f44d378344
49 Ne338cb162f1c4e199b3f1c6e7e0e3a74
50 sg:journal.1294956
51 schema:name Real life evaluation of safinamide effectiveness in Parkinson’s disease
52 schema:pagination 733-739
53 schema:productId N0f535fbf8b724b34bf5cd992eedfd13c
54 N7aaa530b4c4e4eff9aba677ee4258b20
55 N9c3fef2aaa154f9a9821fa83487c40c2
56 Nacdf5166788945b09a203236008e0787
57 Nefda64f57699453d8c00c43ecdc0d66d
58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100993577
59 https://doi.org/10.1007/s10072-018-3272-y
60 schema:sdDatePublished 2019-04-11T00:31
61 schema:sdLicense https://scigraph.springernature.com/explorer/license/
62 schema:sdPublisher N16e6e239c4ba40329a4741025894eb84
63 schema:url http://link.springer.com/10.1007/s10072-018-3272-y
64 sgo:license sg:explorer/license/
65 sgo:sdDataset articles
66 rdf:type schema:ScholarlyArticle
67 N018ee4fce60742df89ae6b07893481ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Male
69 rdf:type schema:DefinedTerm
70 N0f535fbf8b724b34bf5cd992eedfd13c schema:name dimensions_id
71 schema:value pub.1100993577
72 rdf:type schema:PropertyValue
73 N11f0cdf73b7348c4b3dad79b1db8e7ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Alanine
75 rdf:type schema:DefinedTerm
76 N12ff6d87332c4b4dba3b83589c4fbb48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Dose-Response Relationship, Drug
78 rdf:type schema:DefinedTerm
79 N16e6e239c4ba40329a4741025894eb84 schema:name Springer Nature - SN SciGraph project
80 rdf:type schema:Organization
81 N1a20ae4fb51c4991b2c30e0757a23393 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Adult
83 rdf:type schema:DefinedTerm
84 N1a8c29e677be47b4ba993981201011d4 rdf:first Na72df3fd20bc416dab8e3dea440260a0
85 rdf:rest Nd1f4668fc3864f14a13922a6c3b73c7d
86 N1eb5e7e3f1eb449aa104b51e30986db3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Benzylamines
88 rdf:type schema:DefinedTerm
89 N20d09d1eb24e4c429bdd218e7bedc9c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Retrospective Studies
91 rdf:type schema:DefinedTerm
92 N3f91a3b3aa754eaca4407475ad1e273c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Humans
94 rdf:type schema:DefinedTerm
95 N493ce16e0feb4e3ebfaa7eae45e70675 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Treatment Outcome
97 rdf:type schema:DefinedTerm
98 N4e6f0d879c014dda891000950b47311b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Levodopa
100 rdf:type schema:DefinedTerm
101 N7aaa530b4c4e4eff9aba677ee4258b20 schema:name doi
102 schema:value 10.1007/s10072-018-3272-y
103 rdf:type schema:PropertyValue
104 N866c958d2d614105b3d36b98554e9a04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Parkinson Disease
106 rdf:type schema:DefinedTerm
107 N8a2d73614fb64c6aa0ca461684320ffd rdf:first sg:person.01117517756.21
108 rdf:rest N8db9345bba084ac9aad8e3ec354d4652
109 N8db9345bba084ac9aad8e3ec354d4652 rdf:first sg:person.01165766340.84
110 rdf:rest rdf:nil
111 N8fa1ebcf87914df1a25da5f9df66774e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Monoamine Oxidase Inhibitors
113 rdf:type schema:DefinedTerm
114 N925401ab25534ef08c828289faa0b1a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Middle Aged
116 rdf:type schema:DefinedTerm
117 N956bc431d5bc4142aedc93f44d378344 schema:issueNumber 4
118 rdf:type schema:PublicationIssue
119 N9c3fef2aaa154f9a9821fa83487c40c2 schema:name readcube_id
120 schema:value 3db87e55d592dfddadb88300b9664d13c0db67bde3060e508c117851315ddc87
121 rdf:type schema:PropertyValue
122 Na72df3fd20bc416dab8e3dea440260a0 schema:affiliation https://www.grid.ac/institutes/grid.4708.b
123 schema:familyName Lazzeri
124 schema:givenName Giulia
125 rdf:type schema:Person
126 Na9339e73447841babf01dd19abdf77b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Female
128 rdf:type schema:DefinedTerm
129 Nacdf5166788945b09a203236008e0787 schema:name nlm_unique_id
130 schema:value 100959175
131 rdf:type schema:PropertyValue
132 Naf9c5ebee2b74fc486949024744dde7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Aged, 80 and over
134 rdf:type schema:DefinedTerm
135 Nb1306ac8aa884005bafdf497e1a79d1f schema:name Neurology Service, Casa di Cura Humanitas San Pio X, Milan, Italy
136 rdf:type schema:Organization
137 Nb2019440131446fcb2ee06359d6be997 rdf:first sg:person.01351444372.74
138 rdf:rest N1a8c29e677be47b4ba993981201011d4
139 Nb937536ef10f4a87a9e19858925fc10d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Dopamine Agonists
141 rdf:type schema:DefinedTerm
142 Ncabec5b59f5a41b3b75a56fe1823e3cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Aged
144 rdf:type schema:DefinedTerm
145 Nccf9bc08bdfa4159813332802158d303 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Antiparkinson Agents
147 rdf:type schema:DefinedTerm
148 Nd1f4668fc3864f14a13922a6c3b73c7d rdf:first sg:person.0707350751.03
149 rdf:rest Nd9197932dbe14e63b185735ec4645110
150 Nd9197932dbe14e63b185735ec4645110 rdf:first sg:person.01075440114.42
151 rdf:rest N8a2d73614fb64c6aa0ca461684320ffd
152 Nde6c4d1d7b65434c9f1f976b347a4b26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Drug Therapy, Combination
154 rdf:type schema:DefinedTerm
155 Ne338cb162f1c4e199b3f1c6e7e0e3a74 schema:volumeNumber 39
156 rdf:type schema:PublicationVolume
157 Nefda64f57699453d8c00c43ecdc0d66d schema:name pubmed_id
158 schema:value 29441484
159 rdf:type schema:PropertyValue
160 Nf7a12b4ceb8340fb902e2a6707c7acc4 rdf:first sg:person.0635556432.18
161 rdf:rest Nb2019440131446fcb2ee06359d6be997
162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
163 schema:name Medical and Health Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
166 schema:name Neurosciences
167 rdf:type schema:DefinedTerm
168 sg:journal.1294956 schema:issn 1126-5442
169 1590-1874
170 schema:name Neurological Sciences
171 rdf:type schema:Periodical
172 sg:person.01075440114.42 schema:affiliation https://www.grid.ac/institutes/grid.4708.b
173 schema:familyName Silani
174 schema:givenName Vincenzo
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075440114.42
176 rdf:type schema:Person
177 sg:person.01117517756.21 schema:affiliation Nb1306ac8aa884005bafdf497e1a79d1f
178 schema:familyName Lacerenza
179 schema:givenName Marco
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117517756.21
181 rdf:type schema:Person
182 sg:person.01165766340.84 schema:affiliation https://www.grid.ac/institutes/grid.16563.37
183 schema:familyName Comi
184 schema:givenName Cristoforo
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165766340.84
186 rdf:type schema:Person
187 sg:person.01351444372.74 schema:affiliation https://www.grid.ac/institutes/grid.4708.b
188 schema:familyName Di Fonzo
189 schema:givenName Alessio
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351444372.74
191 rdf:type schema:Person
192 sg:person.0635556432.18 schema:affiliation https://www.grid.ac/institutes/grid.418224.9
193 schema:familyName Mancini
194 schema:givenName Francesca
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635556432.18
196 rdf:type schema:Person
197 sg:person.0707350751.03 schema:affiliation https://www.grid.ac/institutes/grid.4708.b
198 schema:familyName Borellini
199 schema:givenName Linda
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707350751.03
201 rdf:type schema:Person
202 sg:pub.10.1007/s00702-012-0930-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038806006
203 https://doi.org/10.1007/s00702-012-0930-8
204 rdf:type schema:CreativeWork
205 sg:pub.10.1007/s40265-015-0389-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017926421
206 https://doi.org/10.1007/s40265-015-0389-7
207 rdf:type schema:CreativeWork
208 https://app.dimensions.ai/details/publication/pub.1074253470 schema:CreativeWork
209 https://app.dimensions.ai/details/publication/pub.1074654105 schema:CreativeWork
210 https://doi.org/10.1001/jamaneurol.2016.4467 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029873011
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1002/mds.22341 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021776403
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1002/mds.23429 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009574356
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1002/mds.25751 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045433382
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/s0960-894x(99)00271-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027208426
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1016/s1353-8020(97)00029-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034520022
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1038/sj.bjp.0703826 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017457033
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1093/brain/123.11.2297 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036535879
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1093/brain/awu195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007870128
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1136/jnnp.55.3.181 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038938753
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1177/0018578717726046 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092203082
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1212/wnl.67.7_suppl_2.s18 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064382308
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1517/13543784.17.7.1115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009120017
235 rdf:type schema:CreativeWork
236 https://doi.org/10.2147/dddt.s77749 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030879020
237 rdf:type schema:CreativeWork
238 https://doi.org/10.2174/156802611798184355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069194220
239 rdf:type schema:CreativeWork
240 https://doi.org/10.3233/jpd-150569 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035973287
241 rdf:type schema:CreativeWork
242 https://www.grid.ac/institutes/grid.16563.37 schema:alternateName University of Eastern Piedmont Amadeo Avogadro
243 schema:name Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
244 rdf:type schema:Organization
245 https://www.grid.ac/institutes/grid.418224.9 schema:alternateName Istituto Auxologico Italiano
246 schema:name Department of Neurology–Stroke Unit and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy
247 rdf:type schema:Organization
248 https://www.grid.ac/institutes/grid.4708.b schema:alternateName University of Milan
249 schema:name Department of Neurology-Stroke Unit and Laboratory of Neuroscience, “Dino Ferrari” Centre - Centre for Neurotechnology and Brain Therapeutics, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
250 Department of Neurology–Stroke Unit and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy
251 Neurology Unit, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, “Dino Ferrari” Center, Neuroscience Section, Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy
252 Neuropathophysiology Unit, IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
253 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...